These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6147492)

  • 21. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
    Ambrus JL; Ambrus CM; Gastpar H; Williams P
    J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo injection of dipyridamole stimulates the synthesis of prostacyclin-like substances in human varicose veins.
    Fahr A; Langer R; Sziegoleit W; Beitz J; Krause P; Förster W
    Biomed Biochim Acta; 1984; 43(3):K6-8. PubMed ID: 6378192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Stimulation of prostacyclin biosynthesis as a possible mechanism of action of dipyridamole (author's transl)].
    Mentz P; Pönicke K; Block HU; Giessler C; Blass KE; Bayer BL; Förster W
    Arzneimittelforschung; 1981; 31(12):2075-82. PubMed ID: 7037009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nafazatrom in thrombocytopenic purpura.
    Copplestone JA; Worsley A; Sadullah S; Hamblin TJ
    Lancet; 1986 Mar; 1(8479):498-9. PubMed ID: 2869229
    [No Abstract]   [Full Text] [Related]  

  • 25. [Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results].
    Gastpar H
    Laryngol Rhinol Otol (Stuttg); 1983 Dec; 62(12):578-85. PubMed ID: 6369051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of nafazatrom-induced inhibition of rat uterus contractions in vitro.
    Cantabrana B; Velasco G; Andrès-Trelles F; Hidalgo A
    Arch Int Pharmacodyn Ther; 1989; 301():285-98. PubMed ID: 2560365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study.
    Costantini V; Talpacci A; Bastiano ML; Boschetti E; Cipolloni S; Bisacci R; Nenci GG
    Biomed Biochim Acta; 1990; 49(4):263-71. PubMed ID: 2119575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet aggregation in arterioles of the hamster cheek pouch and in heart transplants: its tissue-dependent influencibility by acetylsalicylic acid and nafazatrom.
    Herrmann KS; Seuter F
    Haemostasis; 1984; 14(3):281-7. PubMed ID: 6381254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombotic thrombocytopenic purpura: treatment with nafazatrom.
    Williams HJ; Myatt L; Young KD
    Clin Lab Haematol; 1984; 6(2):199-202. PubMed ID: 6386286
    [No Abstract]   [Full Text] [Related]  

  • 30. Nafazatrom in treatment of thrombotic thrombocytopenic purpura.
    Durrant ST; Joosten P; Gordon-Smith EC
    Lancet; 1985 Oct; 2(8459):842. PubMed ID: 2864567
    [No Abstract]   [Full Text] [Related]  

  • 31. Spontaneous atherosclerotic lesions and prostacyclin formation in rabbits: effects of combined dipyridamole and aspirin.
    Lasierra J; Gonzalez J; Aza MJ; Melon J; Vazquez E; Collado PS; Castellarnau C; Rutllant M
    Biomed Biochim Acta; 1989; 48(9):721-5. PubMed ID: 2515856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral nafazatrom in man: effect on inhaled antigen challenge.
    Fuller RW; Maltby N; Richmond R; Dollery CT; Taylor GW; Ritter W; Philipp E
    Br J Clin Pharmacol; 1987 Jun; 23(6):677-81. PubMed ID: 3038156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interference with tumor cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom.
    Maniglia CA; Loulakis PP; Sartorelli AC
    J Natl Cancer Inst; 1986 Apr; 76(4):739-44. PubMed ID: 3457206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575.
    Chamone DA; van Damme B; Carreras LO; Vermylen J
    Haemostasis; 1981; 10(6):297-303. PubMed ID: 7035306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in buffer K+/Na+ ratio modifies the stimulatory effect of the diuretic, cycletanide, upon rat aorta ring prostacyclin synthesis.
    Elliott GR; Braquet P; Bonta IL
    Thromb Res; 1984 Mar; 33(5):549-52. PubMed ID: 6372158
    [No Abstract]   [Full Text] [Related]  

  • 36. Dipyridamole: an antioxidant that promotes the proliferation of aorta smooth muscle cells.
    Morisaki N; Stitts JM; Bartels-Tomei L; Milo GE; Panganamala RV; Cornwell DG
    Artery; 1982; 11(2):88-107. PubMed ID: 6820629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostacyclin production by the deendothelialized rabbit aorta.
    Boeynaems JM; Galand N; Ketelbant P
    J Clin Invest; 1985 Jul; 76(1):7-14. PubMed ID: 3926822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of nafazatrom and indomethacin on pulmonary removal of prostaglandin E1 after endotoxin in rabbits.
    Gillis CN; Havill AM; Moalli R
    Br J Pharmacol; 1987 Aug; 91(4):721-8. PubMed ID: 3311263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.
    Haas CD; Kyle GW; Crissman JD; Schaldenbrand MF
    Invest New Drugs; 1984; 2(1):7-11. PubMed ID: 6469500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.